Weiland O - Search Results

1

Alpha interferon treatment of chronic non-A, non-B hepatitis caused by intravenous gammaglobulin.

Schvarcz R, Weiland O, Glaumann H. Schvarcz R, et al. Among authors: weiland o. Scand J Infect Dis. 1988;20(2):231-2. doi: 10.3109/00365548809032443. Scand J Infect Dis. 1988. PMID: 2456609

2

[Hepatitis C--a review].

Weiland O, Schvarcz R. Weiland O, et al. Lakartidningen. 1992 May 13;89(20):1803-5. Lakartidningen. 1992. PMID: 1317933 Review. Swedish. No abstract available.

3

Hepatitis C: virology, epidemiology, clinical course, and treatment.

Weiland O, Schvarcz R. Weiland O, et al. Scand J Gastroenterol. 1992 May;27(5):337-42. doi: 10.3109/00365529209000084. Scand J Gastroenterol. 1992. PMID: 1326784 Review. No abstract available.

4

Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.

Fuchs D, Norkrans G, Wejstal R, Reibnegger G, Weiss G, Weiland O, Schvarcz R, Fryden A, Wachter H. Fuchs D, et al. Among authors: weiland o. Eur J Med. 1992 Jul-Aug;1(4):196-200. Eur J Med. 1992. PMID: 1341444

5

Seroconversion to hepatitis C virus antibodies in patients with acute posttransfusion non-A, non-B hepatitis in Sweden with a second generation test.

Mattsson L, Grillner L, Weiland O. Mattsson L, et al. Among authors: weiland o. Scand J Infect Dis. 1992;24(1):15-20. doi: 10.3109/00365549209048395. Scand J Infect Dis. 1992. PMID: 1375390

6

Peripheral blood lymphocyte subsets in patients with chronic hepatitis C--effects of interferon treatment.

Wejstål R, Norkrans G, Lenkei R, Weiland O, Schvarcz R, Frydén A. Wejstål R, et al. Among authors: weiland o. Liver. 1992 Aug;12(4 Pt 1):161-7. doi: 10.1111/j.1600-0676.1992.tb01041.x. Liver. 1992. PMID: 1406078 Clinical Trial.

7

Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response.

Struve J, Aronsson B, Frenning B, Granath F, von Sydow M, Weiland O. Struve J, et al. Among authors: weiland o. Scand J Infect Dis. 1992;24(4):423-9. doi: 10.3109/00365549209052627. Scand J Infect Dis. 1992. PMID: 1411307

8

Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.

Wejstål R, Norkrans G, Weiland O, Schvarcz R, Fuchs D, Wachter H, Fryden A, Glaumann H. Wejstål R, et al. Among authors: weiland o. Clin Exp Immunol. 1992 Mar;87(3):340-5. doi: 10.1111/j.1365-2249.1992.tb02999.x. Clin Exp Immunol. 1992. PMID: 1544220 Free PMC article. Clinical Trial.

9

Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.

Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Schvarcz R, et al. Among authors: weiland o. Liver. 1991 Feb;11(1):30-8. doi: 10.1111/j.1600-0676.1991.tb00487.x. Liver. 1991. PMID: 1646369 Clinical Trial.

10

Ribavirin treatment for chronic hepatitis C.

Reichard O, Andersson J, Schvarcz R, Weiland O. Reichard O, et al. Among authors: weiland o. Lancet. 1991 May 4;337(8749):1058-61. doi: 10.1016/0140-6736(91)91707-2. Lancet. 1991. PMID: 1673493 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

263 results

Search Page

Filters